Cargando…
Complete clinical and functional recovery following low-dose methotrexate related paraparesis in a patient with compound c.1298A>C AND c.677C>T MTHFR polymorphism: A case report
RATIONALE: The mechanisms of action of MTX (methotrexate) in the treatment of RA (rheumatoid arthritis) and PsA (psoriatic arthritis) is related to its antifolic activity, due to the high affinity for enzymes that require folate cofactors as dihydrofolate reductase and to the anti-inflammatory activ...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310541/ https://www.ncbi.nlm.nih.gov/pubmed/30544400 http://dx.doi.org/10.1097/MD.0000000000013350 |
_version_ | 1783383456373276672 |
---|---|
author | Saviola, Gianantonio Abdi-Ali, Lul Sacco, Silvano Comini, Laura Plewnia, Katrin Rossi, Maja Orrico, Alfredo |
author_facet | Saviola, Gianantonio Abdi-Ali, Lul Sacco, Silvano Comini, Laura Plewnia, Katrin Rossi, Maja Orrico, Alfredo |
author_sort | Saviola, Gianantonio |
collection | PubMed |
description | RATIONALE: The mechanisms of action of MTX (methotrexate) in the treatment of RA (rheumatoid arthritis) and PsA (psoriatic arthritis) is related to its antifolic activity, due to the high affinity for enzymes that require folate cofactors as dihydrofolate reductase and to the anti-inflammatory activity derivated from the inhibition of thymidylate synthetase that leads to the over-production of adenosine. PATIENT CONCERNS: Our patient was a 41-year-old female, affected by PsA in treatment since 2 years with low-dose methylprednisolone and low-dose subcutaneous MTX. The treatment was effective. The patient subacutely developed a severe paraparesis with impossibility of gait or standing without aid and was admitted to a Neurology Department where the cause of the paraparesis was not clear in spite of accurate radiological neurophysiologic and laboratory tests. Therefore, she was admitted in a rehabilitation unit. DIAGNOSIS AND INTERVENTIONS: Paraparesis in PsA patient in treatment with methotrexate. MTX toxicity was hypothesized; therefore the drug was discontinued while i.m. folic acid and cyanocobalamin were administered for 20 days. The diagnosis was clinical, based on neurological examination (paraparesis) and on the chronic use of MTX (hypothesis of toxicity). OUTCOMES: The patient obtained a complete resolution of paraparesis. Genetic analyses showed associated a compound heterozygosity for the c.1298A>C and c.677C>T variants of methylenetetrahydrofolate reductase (MTHFR) gene. LESSONS: Neurological side effects of MTX are uncommon. In literature no previous case of MTX induced paraparesis in patients treated with low-dose MTX for chronic arthritis has been described. The association between the gene polymorphisms of MTHFR (c.1298A>C and c.677C>T) and MTX toxicity in arthritis patients is confirmed. The case also confirms that folates are a precious antidote of MTX toxicity. |
format | Online Article Text |
id | pubmed-6310541 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-63105412019-01-14 Complete clinical and functional recovery following low-dose methotrexate related paraparesis in a patient with compound c.1298A>C AND c.677C>T MTHFR polymorphism: A case report Saviola, Gianantonio Abdi-Ali, Lul Sacco, Silvano Comini, Laura Plewnia, Katrin Rossi, Maja Orrico, Alfredo Medicine (Baltimore) Research Article RATIONALE: The mechanisms of action of MTX (methotrexate) in the treatment of RA (rheumatoid arthritis) and PsA (psoriatic arthritis) is related to its antifolic activity, due to the high affinity for enzymes that require folate cofactors as dihydrofolate reductase and to the anti-inflammatory activity derivated from the inhibition of thymidylate synthetase that leads to the over-production of adenosine. PATIENT CONCERNS: Our patient was a 41-year-old female, affected by PsA in treatment since 2 years with low-dose methylprednisolone and low-dose subcutaneous MTX. The treatment was effective. The patient subacutely developed a severe paraparesis with impossibility of gait or standing without aid and was admitted to a Neurology Department where the cause of the paraparesis was not clear in spite of accurate radiological neurophysiologic and laboratory tests. Therefore, she was admitted in a rehabilitation unit. DIAGNOSIS AND INTERVENTIONS: Paraparesis in PsA patient in treatment with methotrexate. MTX toxicity was hypothesized; therefore the drug was discontinued while i.m. folic acid and cyanocobalamin were administered for 20 days. The diagnosis was clinical, based on neurological examination (paraparesis) and on the chronic use of MTX (hypothesis of toxicity). OUTCOMES: The patient obtained a complete resolution of paraparesis. Genetic analyses showed associated a compound heterozygosity for the c.1298A>C and c.677C>T variants of methylenetetrahydrofolate reductase (MTHFR) gene. LESSONS: Neurological side effects of MTX are uncommon. In literature no previous case of MTX induced paraparesis in patients treated with low-dose MTX for chronic arthritis has been described. The association between the gene polymorphisms of MTHFR (c.1298A>C and c.677C>T) and MTX toxicity in arthritis patients is confirmed. The case also confirms that folates are a precious antidote of MTX toxicity. Wolters Kluwer Health 2018-12-10 /pmc/articles/PMC6310541/ /pubmed/30544400 http://dx.doi.org/10.1097/MD.0000000000013350 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 |
spellingShingle | Research Article Saviola, Gianantonio Abdi-Ali, Lul Sacco, Silvano Comini, Laura Plewnia, Katrin Rossi, Maja Orrico, Alfredo Complete clinical and functional recovery following low-dose methotrexate related paraparesis in a patient with compound c.1298A>C AND c.677C>T MTHFR polymorphism: A case report |
title | Complete clinical and functional recovery following low-dose methotrexate related paraparesis in a patient with compound c.1298A>C AND c.677C>T MTHFR polymorphism: A case report |
title_full | Complete clinical and functional recovery following low-dose methotrexate related paraparesis in a patient with compound c.1298A>C AND c.677C>T MTHFR polymorphism: A case report |
title_fullStr | Complete clinical and functional recovery following low-dose methotrexate related paraparesis in a patient with compound c.1298A>C AND c.677C>T MTHFR polymorphism: A case report |
title_full_unstemmed | Complete clinical and functional recovery following low-dose methotrexate related paraparesis in a patient with compound c.1298A>C AND c.677C>T MTHFR polymorphism: A case report |
title_short | Complete clinical and functional recovery following low-dose methotrexate related paraparesis in a patient with compound c.1298A>C AND c.677C>T MTHFR polymorphism: A case report |
title_sort | complete clinical and functional recovery following low-dose methotrexate related paraparesis in a patient with compound c.1298a>c and c.677c>t mthfr polymorphism: a case report |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310541/ https://www.ncbi.nlm.nih.gov/pubmed/30544400 http://dx.doi.org/10.1097/MD.0000000000013350 |
work_keys_str_mv | AT saviolagianantonio completeclinicalandfunctionalrecoveryfollowinglowdosemethotrexaterelatedparaparesisinapatientwithcompoundc1298acandc677ctmthfrpolymorphismacasereport AT abdialilul completeclinicalandfunctionalrecoveryfollowinglowdosemethotrexaterelatedparaparesisinapatientwithcompoundc1298acandc677ctmthfrpolymorphismacasereport AT saccosilvano completeclinicalandfunctionalrecoveryfollowinglowdosemethotrexaterelatedparaparesisinapatientwithcompoundc1298acandc677ctmthfrpolymorphismacasereport AT cominilaura completeclinicalandfunctionalrecoveryfollowinglowdosemethotrexaterelatedparaparesisinapatientwithcompoundc1298acandc677ctmthfrpolymorphismacasereport AT plewniakatrin completeclinicalandfunctionalrecoveryfollowinglowdosemethotrexaterelatedparaparesisinapatientwithcompoundc1298acandc677ctmthfrpolymorphismacasereport AT rossimaja completeclinicalandfunctionalrecoveryfollowinglowdosemethotrexaterelatedparaparesisinapatientwithcompoundc1298acandc677ctmthfrpolymorphismacasereport AT orricoalfredo completeclinicalandfunctionalrecoveryfollowinglowdosemethotrexaterelatedparaparesisinapatientwithcompoundc1298acandc677ctmthfrpolymorphismacasereport |